The second quarter was a strategically important period for Annexin, with a focus on taking the next step in the development of ANXV and broadening the development to also include the eye disease diabetic retinopathy (DR). Annexin is currently awaiting approval from the UK Medicines Agency to be able to start a Phase IIa study with ANXV in DR and also newly diagnosed retinal vein occlusion (RVO) as part of the preparatory work for an upcoming Phase IIb study with the aim of evaluating a shorter treatment cycle than previously. In parallel, the company continues its focus on business development and discussions with potential partners for the continued development and commercialization of ANXV.